{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:36:59Z","timestamp":1792442219796,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40257-020-00583-3","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T03:03:26Z","timestamp":1614740606000},"page":"243-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial"],"prefix":"10.1007","volume":"22","author":[{"given":"Elaine C.","family":"Siegfried","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-3817","authenticated-orcid":false,"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-667X","authenticated-orcid":false,"given":"Lisa A.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5633-0178","authenticated-orcid":false,"given":"Lynda C.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-5460","authenticated-orcid":false,"given":"Randy","family":"Prescilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-9642","authenticated-orcid":false,"given":"Paola","family":"Mina-Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-6486","authenticated-orcid":false,"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"583_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327\u201349.","journal-title":"J Am Acad Dermatol."},{"key":"583_CR2","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","volume":"26","author":"J Ring","year":"2012","unstructured":"Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol. 2012;26:1176\u201393.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"583_CR3","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjd.15928","volume":"178","author":"AM Drucker","year":"2018","unstructured":"Drucker AM, Eyerick K, de Bruin-Weller M, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178:768\u201375.","journal-title":"Br J Dermatol."},{"key":"583_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","volume":"77","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77:623\u201333.","journal-title":"J Am Acad Dermatol."},{"key":"583_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.","journal-title":"Allergy Asthma Clin Immunol."},{"key":"583_CR6","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111:5147\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"583_CR7","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111:5153\u20138.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"583_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13:425\u201337.","journal-title":"Expert Rev Clin Immunol."},{"key":"583_CR9","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Martin J, et al. Dupilumab protects from type 2 inflammation by impacting both systemic and local inflammatory events downstream of IL-4\/IL-13 signalling. Allergy. 2020;75:1188\u2013204.","journal-title":"Allergy"},{"key":"583_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335\u201348.","journal-title":"N Engl J Med."},{"key":"583_CR11","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287\u2013303.","journal-title":"Lancet"},{"key":"583_CR12","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to cyclosporine A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178:1083\u2013101.","journal-title":"Br J Dermatol."},{"key":"583_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156:44\u201356.","journal-title":"JAMA Dermatol."},{"key":"583_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82:377\u201388.","journal-title":"J Am Acad Dermatol."},{"key":"583_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjd.18476","volume":"182","author":"MJ Cork","year":"2020","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182:85\u201396.","journal-title":"Br J Dermatol."},{"key":"583_CR16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182:1120\u201335.","journal-title":"Br J Dermatol."},{"key":"583_CR17","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE); version 5.0. November 27, 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 20 Dec 2019."},{"key":"583_CR18","unstructured":"Nordic MPN Study Group. Guidelines for the diagnosis and treatment of eosinophilia. 3rd version. May 2018. https:\/\/www.nmpn.org\/index.php\/guidelines\/18-care-program-for-the-diagnosis-and-treatment-of-eosinophilia-3rd-version-may-2018\/file. Accessed 20 Aug 2020."},{"key":"583_CR19","first-page":"e262","volume":"168","author":"M Dogru","year":"2017","unstructured":"Dogru M, Citli R. The neutrophil-lymphocyte ratio in children with atopic dermatitis: a case-control study. Clin Ter. 2017;168:e262\u20135.","journal-title":"Clin Ter."},{"key":"583_CR20","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.12659\/MSM.900212","volume":"23","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Ma W. Assessment of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in atopic dermatitis patients. Med Sci Monitor. 2017;23:1340\u20136.","journal-title":"Med Sci Monitor."},{"key":"583_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1365-2230.1990.tb02086.x","volume":"15","author":"M Uehara","year":"1990","unstructured":"Uehara M, Izukura R, Sawai T. Blood eosinophilia in atopic dermatitis. Clin Exp Dermatol. 1990;15:264\u20136.","journal-title":"Clin Exp Dermatol."},{"key":"583_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000247419","volume":"185","author":"MK Kagi","year":"1992","unstructured":"Kagi MK, Joller-Jemelka H, W\u00fcthrich B. Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology. 1992;185:88\u201392.","journal-title":"Dermatology"},{"key":"583_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1046\/j.1365-2133.2001.04456.x","volume":"145","author":"P Kiehl","year":"2001","unstructured":"Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol. 2001;145:720\u20139.","journal-title":"Br J Dermatol."},{"key":"583_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12016-011-8252-4","volume":"41","author":"F-T Liu","year":"2011","unstructured":"Liu F-T, Goodarzi H, Chen H-Y. IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allerg Immunol. 2011;41:298\u2013310.","journal-title":"Clin Rev Allerg Immunol."},{"key":"583_CR25","first-page":"535","volume":"35","author":"E De Grauuw","year":"2015","unstructured":"De Grauuw E, Beltraminelli H, Simon HU, et al. Eosinophilia in dermatologic disorders. Immunol Allergy Clin N Am. 2015;35:535\u201360.","journal-title":"Immunol Allergy Clin N Am."},{"key":"583_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","volume":"138","author":"T Werfel","year":"2016","unstructured":"Werfel T, Allam J-P, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138:336\u201349.","journal-title":"J Allergy Clin Immunol."},{"key":"583_CR27","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord I, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med."},{"key":"583_CR28","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"K Rabe","year":"2018","unstructured":"Rabe K, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475\u201385.","journal-title":"N Engl J Med."},{"key":"583_CR29","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638\u201350.","journal-title":"Lancet"},{"key":"583_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1346-8138.1990.tb01679.x","volume":"17","author":"H Mukai","year":"1990","unstructured":"Mukai H, Noguchi T, Kamimura K, Nishioka K, Nishiyama S. Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol. 1990;17:477\u201381.","journal-title":"J Dermatol."},{"key":"583_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00403-011-1198-9","volume":"304","author":"K Kou","year":"2012","unstructured":"Kou K, Alhara M, Matsunaga T, et al. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. Arch Dermatol Res. 2012;304:305\u201312.","journal-title":"Arch Dermatol Res."},{"key":"583_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","volume":"15","author":"J Thijs","year":"2015","unstructured":"Thijs J, Krastev T, Weidinger S, et al. Biomarkers for atopic dermatitis: a systemic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015;15:453\u201360.","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"583_CR33","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","volume":"138","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Villarreal M, Jepson B, et al. Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype. J Investig Dermatol. 2018;138:2224\u201333.","journal-title":"J Investig Dermatol."},{"key":"583_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4274\/jcrpe.v3i1.02","volume":"3","author":"S Turan","year":"2011","unstructured":"Turan S, Topcu B, G\u00f6k\u00e7e \u0130, et al. Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets. J Clin Res Pediatr Endocrinol. 2011;3:7\u201311.","journal-title":"J Clin Res Pediatr Endocrinol."},{"key":"583_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamadermatol.2014.3432","volume":"151","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI, Paller AS. Association between eczema and stature in 9 US population-based studies. JAMA Dermatol. 2015;151:401\u20139.","journal-title":"JAMA Dermatol."},{"key":"583_CR36","unstructured":"JAKAFI\u00ae (ruxolitinib). Highlights of prescribing information. US FDA 2017. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202192s015lbl.pdf. Accessed 20 Dec 2019."},{"key":"583_CR37","unstructured":"XELJANZ\u00ae (tofacitinib). Highlights of prescribing information. US FDA 2018. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf. Accessed 20 Dec 2019."},{"key":"583_CR38","unstructured":"OLUMIANT\u00ae (baricitinib). Highlights of prescribing information. US FDA 2017. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf. Accessed 20 Dec 2019."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-020-00583-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T06:22:55Z","timestamp":1616048575000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-020-00583-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["583"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00583-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"16 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. (ClinicalTrials.gov identifier: NCT03054428). The study sponsors participated in the study design; collection, analysis, and interpretation of the data; writing of the report; and the decision to submit the article for publication. Medical writing and editorial assistance were provided by Alexandre Houzelle, PhD, and Vicki Schwartz, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Elaine C. Siegfried: Dermavant, Eli Lilly, Pfizer, Regeneron Pharmaceuticals, Inc., Verrica\u2014consultant; GlaxoSmithKline, LEO Pharma, Novan, Pfizer\u2014data and safety monitoring board; Eli Lilly, Janssen, Regeneron Pharmaceuticals, Inc., Stiefel, Verrica\u2014Principal Investigator in clinical trials. Thomas Bieber: AbbVie, Almirall, AnaptysBio, Arena, Asana Biosciences, Astellas, BioVersys, Boehringer Ingelheim, Daichi Sankyo, Davos Biosciences, Dermavant\/Roivant Sciences, DS Pharma, Eli Lilly, Evaxion Biotech, FLX Bio, Galapagos\/MorphoSys, Galderma, Glenmark, GlaxoSmithKline, Incyte, Kymab, LEO Pharma, L\u00b4Or\u00e9al, Menlo Therapeutics, Novartis, Pfizer, Pierre Fabre, Sanofi\/Regeneron Pharmaceuticals, Inc., UCB\u2014lecturer and\/or consultant. Eric L. Simpson: AbbVie, Celgene, Eli Lilly, Galderma, Kyowa Hakko Kirin, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Tioga\u2014grants; AbbVie, Boehringer Ingelheim, Dermavant, Dermira, Eli Lilly, Forte Bio, Incyte, LEO Pharma, MedImmune, Menlo Therapeutics, Ortho Dermatologics, Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron Pharmaceuticals, Inc., Sanofi, Valeant\u2014personal fees. Amy S. Paller: AbbVie, AnaptysBio, Celgene, Eli Lilly, Galderma, Incyte, KrystalBio, LEO Pharma, Janssen, Novartis, Regeneron Pharmaceuticals, Inc.\u2014investigator; AbbVie, Abeona Therapeutics, Almirall, Amgen, Asana Biosciences, Boehringer Ingelheim, Dermavant, Dermira, Eli Lilly, Exicure, Forte, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Sol Gel, UCB\u2014consultant with honorarium. Lisa A. Beck: AbbVie, Allakos, Arena Pharma, AstraZeneca, BenevolentAI, Connect Biopharma, Eli Lilly, Incyte, LEO Pharma, Novartis, Pfizer, Principia Biopharma, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi, UCB, Vimalan\u2014consultant. AbbVie, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi\u2014investigator; 3M, Gilead, Medtronics, Moderna\u2014owns stocks. Mark Boguniewicz: Regeneron Pharmaceuticals, Inc.\u2014investigator; Regeneron Pharmaceuticals, Inc., Sanofi Genzyme\u2014consultant. Lynda C. Schneider: Regeneron Pharmaceuticals, Inc., DBV Technologies\u2014investigator; Genentech\u2014research support; AbbVie\u2014consultant. Faisal A. Khokhar, Zhen Chen, Paola Mina-Osorio, Ashish Bansal: Regeneron Pharmaceuticals, Inc.\u2014employees and shareholders. Randy Prescilla: Sanofi Genzyme\u2014employee, may hold stock and\/or stock options in the company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted following the ethical principles that derive from the Declaration of Helsinki, International Conference on Harmonization guidelines, Good Clinical Practice, and local applicable regulatory requirements. The trial was overseen by an independent data and safety monitoring board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients and the patients\u2019 parents\/guardians prior to commencement of any study treatment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AB contributed to study concept and design. ECS, TB, ELS, ASP, LAB, MB, and LCS acquired data. ZC conducted the statistical analyses on the data. AB drafted the manuscript with the medical writer and created figures. ECS, TB, ELS, ASP, LAB, MB, LCS, FAK, ZC, RP, PM-O, and AB interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}